HC Wainwright Reaffirms “Neutral” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $21.50 price objective on the stock, down from their prior price objective of $22.00. HC Wainwright’s price objective indicates a potential upside of 0.80% from the stock’s current price.

Several other analysts have also weighed in on DAWN. JonesTrading lowered shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and raised their price objective for the stock from $20.00 to $21.50 in a report on Friday. Needham & Company LLC downgraded Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Wedbush restated a “neutral” rating and set a $21.50 target price (down from $30.00) on shares of Day One Biopharmaceuticals in a report on Monday. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday. Finally, Zacks Research lowered shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals has an average rating of “Hold” and an average target price of $24.44.

Day One Biopharmaceuticals Price Performance

DAWN opened at $21.33 on Tuesday. The company has a market capitalization of $2.20 billion, a P/E ratio of -20.71 and a beta of -1.25. The firm’s fifty day moving average price is $11.34 and its two-hundred day moving average price is $9.18. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $21.40.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The business had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. On average, equities research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Michael Vasconcelles sold 2,728 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $31,644.80. Following the transaction, the insider owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Charles N. York II sold 6,065 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares of the company’s stock, valued at $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 36,461 shares of company stock worth $422,948 over the last 90 days. Insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of DAWN. Vanguard Group Inc. increased its holdings in Day One Biopharmaceuticals by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock worth $58,552,000 after buying an additional 101,047 shares during the last quarter. Vestal Point Capital LP raised its stake in Day One Biopharmaceuticals by 94.4% in the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after acquiring an additional 2,525,000 shares during the period. Deerfield Management Company L.P. boosted its position in Day One Biopharmaceuticals by 26.4% during the third quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock worth $33,173,000 after purchasing an additional 982,282 shares during the period. State Street Corp raised its position in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. State Street Corp now owns 4,289,566 shares of the company’s stock valued at $39,979,000 after purchasing an additional 1,049,122 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Day One Biopharmaceuticals by 2.0% during the 2nd quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock worth $26,635,000 after buying an additional 79,255 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals News Summary

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Servier agreed to acquire Day One for $21.50 per share in a roughly $2.5 billion deal, valuing DAWN at a takeover premium and prompting a large jump in the stock as investors price in the cash consideration. DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
• Positive Sentiment: Pre-market trading showed a >65% surge as the market reacted to the acquisition news, driving volume and lifting the market cap toward the deal valuation. DAWN Stock Jumps Over 65% in Pre-Market After $2.5 Billion Servier Acquisition Deal
• Neutral Sentiment: Reported short interest data appears to show 0 shares and a 0.0 days short-interest ratio (likely a non‑informative or reporting artifact), indicating no clear short‑sell pressure detected in the published snapshot.
• Neutral Sentiment: Broader market and press summaries (coverage pages) updated DAWN’s profile following the takeover announcement; useful for context but not new catalysts. Day One Biopharmaceuticals Inc. (Barron’s)
• Negative Sentiment: Several brokers cut DAWN to “Hold” (JonesTrading, Needham, Wedbush) after the deal news—these ratings reflect the stock trading near the bid/offer level and reduce near-term analyst-driven upside. Day One Biopharmaceuticals (NASDAQ:DAWN) Cut to Hold at JonesTrading
• Negative Sentiment: Wedbush reaffirmed a “neutral” stance and lowered its price target to $21.50 (from $30), signaling limited upside beyond the offer price. Wedbush note via Benzinga
• Negative Sentiment: A PR Newswire piece flagged shareholder fairness concerns, noting insiders may receive outsized benefits and that transaction terms could limit competing bids—this raises potential governance and deal-process risk that could attract activist scrutiny or procedural challenges. Are DAWN and TALK Obtaining Fair Deals for their Shareholders?

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.